2026 NPPES data Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician NPI 1760101778 MD
Verify on CMS →

IRMAK KARACA, MD

Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician in NEW YORK, New York. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
282
Medicare Part D claims · 99 beneficiaries · Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician avg: 642
Generic prescribing
64%
generic claims · 36% brand-name · higher generic rates reduce patient out-of-pocket costs
MIPS score
76.5025/100
▼ 7 pts below national avg 83.1 · [object Object]
Industry payments
$710.72
9 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

IRMAK KARACA, MD reported a CMS MIPS final score of 76.5025/100 — below the 83.1 national average — and filed 282 Medicare Part D claims in 2023.

76.5025/100
MIPS score · -7 vs avg
282
Part D claims, 2023
64%
generic prescribing
Likely
board-certified (heuristic)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

IRMAK KARACA, MD's MIPS score vs every scored U.S. clinician

CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure

77 21st percentile higher than 21% of 477,587 scored providers

0–10: 8,684 scored providers (2%). Below this entry. 10–20: 3,008 scored providers (1%). Below this entry. 20–30: 3,069 scored providers (1%). Below this entry. 30–40: 2,746 scored providers (1%). Below this entry. 40–50: 2,928 scored providers (1%). Below this entry. 50–60: 5,882 scored providers (1%). Below this entry. 60–70: 13,906 scored providers (3%). Below this entry. 70–80: 118,074 scored providers (25%). This entry sits in this band. 80–90: 129,887 scored providers (27%). Above this entry. 90–100: 189,403 scored providers (40%). Above this entry. This provider 0 100 every MIPS-scored clinician, bucketed by value

Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Merit-based Incentive Payment System (MIPS) · 2023

Board certification likely (heuristic — not verified)

IRMAK KARACA, MD practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting + 1 hospital affiliation — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).

What does the federal data show about IRMAK KARACA, MD?

Below national average

NPI registry status

Active

Issued 08/23/2022

NPI 1760101778

Primary specialty

Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician

Rare

37 US NPIs in this specialty

Medicare Part D claims

282 56% vs specialty avg

2023 prescription claims

Specialty avg: 642

MIPS final score

76.5025/100 6.597499999999997% pts

Above neutral band

vs 83.1 national avg

Specialty distribution in New York

How Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician compares to other specialties among New York providers

New York providers

Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician share within New York

1. Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician share within New York

Medicare quality performance — MIPS

IRMAK KARACA, MD's 2023 MIPS final score plotted against the Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician national average

Below national average
MIPS Final Score
76.5025/100
vs 83.1 national avg · 2023 performance year

MIPS final score (Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician) — 76.5025/100 vs national avg 83.1

0%100%National avg83%76.5%
MIPS final score (Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician) — 76.5025/100 vs national avg 83.1

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

IRMAK KARACA, MD appears in the CMS NPPES registry as a Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician provider holding MD credentials at 622 W 168TH ST, NEW YORK, NY, 10032, with a listed phone of (212) 305-9535. NPI 1760101778 was issued on 08/23/2022. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what KARACA most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 282 prescription claims written by this provider, covering 99 Medicare beneficiaries and totaling roughly $252K in drug spend, split 36% brand-name and 64% generic by claim count. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 76.5025/100 for the 2023 performance year (Quality 74.3195, Cost 43.9595), compared with the national average of 83.1.

Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician is a narrow specialty nationwide, with 37 enrolled providers across 15 states and an average of 642 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

622 W 168TH ST
NEW YORK, NY 10032

Provider Details

NPI 1760101778
Specialty Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician
Credentials MD
Gender Female
NPI Issued 08/23/2022

CMS Quality Score (MIPS)

Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.

76.5025
Final Score
Avg: 83.1
74.3195
Quality
43.9595
Cost
100
Promoting Interoperability

Reporting: Group practice

Hospital and facility affiliations

Facilities where IRMAK KARACA, MD bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" — a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.

TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
NEW YORK, NY

Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for IRMAK KARACA, MD. Source: openpaymentsdata.cms.gov.

Total received

$711

Largest payer

Genentech USA, Inc.

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

License & disciplinary context — New York NYSBPMC 2023 annual report

Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~100K New York medical licensees in 2023 — they are NOT specific to IRMAK KARACA, MD. To verify IRMAK KARACA, MD's current license status, search the NYSBPMC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.

312
Total board actions, New York 2023
Across 302 cases
3.12
Actions per 1,000 licensees
New York statewide rate
probation
Most common action type
89 cases

NYSBPMC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the New York disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.

Brand vs generic prescribing mix · Above average

IRMAK KARACA, MD — brand share 36.0%
Specialty average (est.)

36% brand-name claims vs 64% generic, on 282 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

282
Total Claims
$252K
Total Drug Cost
99
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
468
Total Day Supply
13,429
Brand vs Generic
36% brand / 64% generic
Brand Drug Cost
$210K
Generic Drug Cost
$42K

Patient Demographics

Average Patient Age
71.2 years
Avg HCC Risk Score
1.55
Gender Split
59% female / 41% male
Age Distribution
<65: 13, 65-74: 47, 75-84: 27, 85+: 12

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

What IRMAK KARACA, MD prescribes most

Top Medicare Part D drugs by claim count, 2023

claims
Source CMS Medicare Part D Prescriber Public Use File As of 2023
Drug Claims
Prednisone
33
Prednisolone Acetate
27
Methotrexate
Methotrexate Sodium
23
Ketorolac Tromethamine
20
Mycophenolate Mofetil
19
Valacyclovir
Valacyclovir Hcl
12
Dorzolamide-Timolol
Dorzolamide Hcl/Timolol Maleat
11
Humira(Cf) Pen
Adalimumab
11
Neoral
"Cyclosporine
N/A

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician Overview

How IRMAK KARACA, MD fits within the Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician landscape nationally.

37
Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician Providers in US
15
States with Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician
642
Avg Claims per Provider

IRMAK KARACA, MD's 282 claims are below the specialty average of 642.

Nearby Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician Providers in New York

Other clinicians with the same primary specialty enrolled in New York, drawn from the same CMS NPPES roster as KARACA.

Compare Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician nationally: see state-by-state distribution →

Frequently Asked Questions

What is IRMAK KARACA, MD's specialty?
IRMAK KARACA, MD specializes in Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician and practices in NEW YORK, New York. Credentials: MD.
How much does IRMAK KARACA, MD prescribe under Medicare Part D?
In 2023, IRMAK KARACA, MD wrote 282 Medicare Part D claims totaling $252K in drug costs for 99 beneficiaries.
What is IRMAK KARACA, MD's Medicare quality score?
IRMAK KARACA, MD has a CMS MIPS Final Score of 76.5025/100 (Quality: 74.3195, Cost: 43.9595). The national average MIPS Final Score is 83.1. Source: CMS Merit-based Incentive Payment System (MIPS) 2023.
Where is IRMAK KARACA, MD located?
IRMAK KARACA, MD is located at 622 W 168TH ST, NEW YORK, NY, 10032. Phone: (212) 305-9535.
What is IRMAK KARACA, MD's NPI number?
IRMAK KARACA, MD's National Provider Identifier (NPI) is 1760101778, issued on 08/23/2022.
Does IRMAK KARACA, MD prescribe more brand-name or generic drugs?
IRMAK KARACA, MD's prescribing is 36% brand-name and 64% generic drugs by claim count, with $210K in brand drug costs.
How many Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician providers are there in the US?
There are 37 Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician providers across 15 states in the US. The average Uveitis and Ocular Inflammatory Disease (Ophthalmology) Physician provider writes 642 Medicare Part D claims per year.
What drugs does IRMAK KARACA, MD prescribe most often?
Based on 2023 Medicare Part D data, IRMAK KARACA, MD's most frequently prescribed drugs include Prednisone, Prednisolone Acetate, Methotrexate. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does IRMAK KARACA, MD accept Medicare?
IRMAK KARACA, MD appears in CMS Medicare data with 282 Part D claims and 99 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify IRMAK KARACA, MD's credentials?
IRMAK KARACA, MD's NPI is 1760101778 with credentials MD. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Quality Performance
CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology